Pronota and Molecuence Announce Collaboration in Protein Biomarker Discovery
Pronota NV announced that it has entered into an agreement
with Molecuence Corporation, a wholly owned subsidiary of Mitsubishi Chemical
Corporation, to discover and validate protein biomarkers in stroke. Pronota
will apply its proven proprietary platforms for protein biomarker discovery
(MASStermind®) and biomarker verification (MASSterclass™) to this project. The
financial terms have not been disclosed.
National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.